Literature DB >> 22425534

1st International consensus guidelines for advanced breast cancer (ABC 1).

F Cardoso1, A Costa, L Norton, D Cameron, T Cufer, L Fallowfield, P Francis, J Gligorov, S Kyriakides, N Lin, O Pagani, E Senkus, C Thomssen, M Aapro, J Bergh, A Di Leo, N El Saghir, P A Ganz, K Gelmon, A Goldhirsch, N Harbeck, N Houssami, C Hudis, B Kaufman, M Leadbeater, M Mayer, A Rodger, H Rugo, V Sacchini, G Sledge, L van't Veer, G Viale, I Krop, E Winer.   

Abstract

The 1st international Consensus Conference for Advanced Breast Cancer (ABC 1) took place on November 2011, in Lisbon. Consensus guidelines for the management of this disease were developed. This manuscript summarizes these international consensus guidelines.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22425534     DOI： 10.1016/j.breast.2012.03.003

Source DB:  PubMed          Journal:  Breast        ISSN： 0960-9776            Impact factor:   4.380


  86 in total

Review 1.  Management of locally advanced breast cancer-perspectives and future directions.

Authors:  Konstantinos Tryfonidis; Elzbieta Senkus; Maria J Cardoso; Fatima Cardoso
Journal:  Nat Rev Clin Oncol       Date:  2015-02-10       Impact factor: 66.675

2.  Integrating genetic and genomic information into effective cancer care in diverse populations.

Authors:  L Fashoyin-Aje; K Sanghavi; K Bjornard; J Bodurtha
Journal:  Ann Oncol       Date:  2013-10       Impact factor: 32.976

3.  SEOM clinical guidelines for the management of metastatic breast cancer 2013.

Authors:  A Llombart Cussac; J de la Haba Rodríguez; A Ruiz Simón; I Álvarez López; J Cortés Castán
Journal:  Clin Transl Oncol       Date:  2013-10-23       Impact factor: 3.405

4.  ABC4 Consensus: Assessment by a German Group of Experts.

Authors:  Nadia Harbeck; Diana Lüftner; Norbert Marschner; Michael Untch; Doris Augustin; Susanne Briest; Johannes Ettl; Renate Haidinger; Lothar Müller; Volkmar Müller; Eugen Ruckhäberle; Rachel Wuerstlein; Christoph Thomssen
Journal:  Breast Care (Basel)       Date:  2018-02-15       Impact factor: 2.860

5.  Which patients with metastatic breast cancer benefit from subsequent lines of treatment? An update for clinicians.

Authors:  Raffaella Palumbo; Federico Sottotetti; Alberto Riccardi; Cristina Teragni; Emma Pozzi; Erica Quaquarini; Barbara Tagliaferri; Antonio Bernardo
Journal:  Ther Adv Med Oncol       Date:  2013-11       Impact factor: 8.168

Review 6.  Optimal sequencing of anti-HER2 therapy throughout the continuum of HER2-positive breast cancer: evidence and clinical considerations.

Authors:  Nadia Harbeck; Rachel Wuerstlein
Journal:  Drugs       Date:  2013-10       Impact factor: 9.546

Review 7.  Oligometastatic breast cancer: a shift from palliative to potentially curative treatment?

Authors:  Simona Di Lascio; Olivia Pagani
Journal:  Breast Care (Basel)       Date:  2014-02       Impact factor: 2.860

8.  Perceptions and needs of women with metastatic breast cancer: a focus on clinical trials.

Authors:  Zeina A Nahleh; Nancy U Lin; Antonio C Wolff; Fatima Cardoso
Journal:  Breast       Date:  2013-03-25       Impact factor: 4.380

Review 9.  Trastuzumab emtansine: a review of its use in patients with HER2-positive advanced breast cancer previously treated with trastuzumab-based therapy.

Authors:  Sohita Dhillon
Journal:  Drugs       Date:  2014-04       Impact factor: 9.546

Review 10.  Everolimus in combination with exemestane: a review of its use in the treatment of patients with postmenopausal hormone receptor-positive, HER2-negative advanced breast cancer.

Authors:  Sohita Dhillon
Journal:  Drugs       Date:  2013-04       Impact factor: 9.546
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.